Alexion Pharmaceuticals, Inc.
NASDAQ: ALXN
$182.50
+$0.00 (+0.0%)
Closing Price on July 28, 2021
ALXN Articles
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
Published:
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.
Published:
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
Published:
These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
Published:
24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a single tweet did to them last week.
Published:
The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
Published:
Oppenheimer maintained its Outperform rating for Alexion Pharmaceuticals with a price target that implies upside of more than 40%.
Published:
Monday's top analyst upgrades, downgrades and initiations include AeroVironment, Gold Fields, Marvell Technology, Nokia and Silver Wheaton.
Published:
The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased across the board for this settlement date.
Published:
The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks.
Published:
In a new research report, JPMorgan highlights its favorite biotech stocks to buy after the second-quarter earnings print.
Published:
The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech stocks backed off for this period.
Published:
Merrill Lynch has looked at large cap biotech leaders and how interest rate increases may play a part in stock performance.
Published:
In a new research report, Cowen's well-respected analyst Ken Cacciatore makes a very good case that some huge, high-profile biotech companies could be targeted for buyouts.
Published:
ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break...
Published:
Last Updated: